Acumen Pharmaceuticals, Inc. (ABOS) financial statements and ratios from SEC XBRL: revenue $7.45M (TTM), net margin -1629.3%, revenue growth -44.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $7.45M |
| Net Margin | -1629.3% |
| Revenue Growth (YoY) | -44.9% |
| EPS Growth (YoY) | -33.8% |
| FCF Growth (YoY) | -43.2% |
| Price / Book | 3.99 |
| Price / Sales | 44.44 |
| FCF Yield | -40.2% |
| Altman Z-Score | -4.84 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ABOS overview · ABOS earnings · ABOS KPIs · ABOS investor relations · ABOS ownership · ABOS peers · ABOS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.